11QH
Crystal structure of Serine/threonine-protein kinase 33 (STK33) Kinase Domain in complex with inhibitor CDD-3094
This is a non-PDB format compatible entry.
Summary for 11QH
| Entry DOI | 10.2210/pdb11qh/pdb |
| Related | 8VF6 |
| Descriptor | Serine/threonine-protein kinase 33, (2,6-diazaspiro[3.5]nonan-2-yl)(3-{[(2M)-2-(pyridin-3-yl)phenyl]ethynyl}-1H-indazol-5-yl)methanone, ASPARAGINE, ... (4 entities in total) |
| Functional Keywords | serine/threonine-protein kinase 33, kinase inhibitor, transferase, transferase-inhibitor complex, transferase/inhibitor |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 4 |
| Total formula weight | 135141.48 |
| Authors | |
| Primary citation | Ku, A.F.,Ta, H.M.,Wang, Y.,Kaown, G.,Sharma, K.L.,Bohren, K.M.,Qin, X.,Wang, J.,Jimmidi, R.,Madasu, C.,Miao, Q.,Sankaran, B.,Teng, M.,Tan, Z.,Chamakuri, S.,Li, F.,Young, D.W.,Kim, C.,Matzuk, M.M. Design, Synthesis, and Pharmacological Profiling of Serine/Threonine Kinase 33 (STK33) Inhibitors for Nonhormonal Male Contraception. J.Med.Chem., 69:23564-23584, 2026 Cited by PubMed Abstract: Serine/threonine kinase 33 (STK33) is a male germ-specific nonhormonal contraceptive target that is both genetically and chemically validated. Building on our previously reported reversible male contraceptive inhibitor, CDD-2807, we conducted systematic structure-activity relationship (SAR) and structure-property relationship (SPR) studies on the 3-(biphenylethynyl)-1H-indazole scaffold to address key drug development liabilities, most notably poor kinetic solubility. These efforts identified CDD-3094, which exhibits a balanced profile characterized by retained nanomolar cellular potency, >100 μM kinetic solubility, comparable metabolic stability, reduced human ether-à-go-go-related gene (hERG) channel inhibition, and a favorable cellular kinase profile, with 278 of 300 kinases (92.7%) displaying <30% occupancy at 1000 nM. Leveraging X-ray crystallography of the STK33/CDD-3094 complex, we performed structure-based modifications to specifically target the primary off-target liability, CDC-like kinase 4 (CLK4). This work culminated in the discovery of compound 40, which achieved 446-fold biochemical selectivity for STK33 over CLK4. While its cellular potency is attenuated to >1 μM, this analog provides a valuable biochemical tool for investigating STK33 selectivity and highlights the challenges of balancing kinase discrimination with intracellular activity. Collectively, these studies establish a foundation for developing soluble STK33 inhibitors, facilitating further preclinical refinement of nonhormonal male contraceptives. PubMed: 42911738DOI: 10.1021/acs.jmedchem.6c00790 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.9 Å) |
Structure validation
Download full validation report






